Study to Investigate the effects single oral dose of AZD1386 (Capsaicin)

Study identifier:D5090C00009

ClinicalTrials.gov identifier:N/A

EudraCT identifier:N/A

CTIS identifier:N/A

Study Complete

Official Title

A double-blind, randomized, single-centre, placebo-controlled, crossover study to investigate the effects of a single oral dose of AZD1386 on intradermal capsaicin evoked pain symptoms and heat sensitivity in healthy volunteers

Medical condition

Capsaicin evoked pain

Phase

Phase 1

Healthy volunteers

Yes

Study drug

AZD1386, Placebo

Sex

All

Actual Enrollment

Study type

Interventional

Age

20 Years - 45 Years

Date

Study Start Date: 01 Jan 2008

Primary Completion Date: 01 May 2008

Study Completion Date: 01 May 2008

Study design

Allocation: Randomized
Endpoint Classification: Pharmacokinetics/dynamics Study
Intervention Model: Crossover Assignment
Masking: Double Blind
Primary Purpose: Treatment

Verification:

Verified 01 Nov 2013 by AstraZeneca Pharmaceuticals

Collaborators

Inclusion and exclusion criteria

No locations available

Arms	Assigned Interventions
Experimental: 1 36 subjects receiving a specified volume of the active component AZD1386 in a single dose.	Drug: AZD1386 Oral solution fixed dose (95 mg given orally on two occasions)
Placebo Comparator: 2 36 subjects receiving a specified volume of placebo in a single dose.	Drug: Placebo Oral solution fixed dose (95 mg given orally on two occasions)

"There is no result for the study"

Documents available

https://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_MED_6111&studyid=466&filename=CSR-D5090C00009.pdf
Download
CSR-D5090C00009.pdf
Download
Trial Results Summaries
Available here

Contacts

Contact

AstraZeneca Clinical Study Information

800-236-9933

information.center@astrazeneca.com

Investigators

Principal Investigator

Agneta Berg

AstraZeneca R&D Södertälje